News articles featuring quotes from Real Endpoints

<>

July 25, 2018

Managed Care

Must Sky-High Prices ‘Come on Down’ Before the Price Is Right?

by Richard Mark Kirkner

The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?

read full article >

June 15, 2018

BioCentury

Safer Harbor

by Steve Usdin

FDA guidance released on June 12 broadens a safe harbor that allows medical product manufacturers to communicate with payers, PBMs, formulary committees and similar entities. A primary goal is to make it easier to base payments on outcomes not mentioned on product labels, but there could be broader effects in the loosened restrictions oncommunications between medical product developers and payers.

read full article >

April 9, 2018

BioCentury

Part D Sour Spot

by Steve Usdin

A law that comes into effect next year will squeeze profits from moderately priced drugs that treat common, chronic conditions and increase economic incentives to develop high priced medicines for rare or acute life-threatening diseases. Manufacturers of drugs to treat common, chronic conditions will be especially hard hit.

read full article >

March 8, 2018

Financial Times

Cigna grabs vital scale with $67bn deal for Express Scripts

by David Crow

Express Scripts was the last large independent pharmacy benefits manager, or PBM, in the US. A PBM acts as a middleman in negotiations between drugmakers and the payers (i.e. employers, insurers, and government), which buy medicines in the US. With its $67 billion takeover of Express Scripts, health insurer Cigna is sending a signal that it will have to get bigger to deal with the most pressing malady of US healthcare: soaring costs. By buying Express Scripts, Cigna hopes to gain more scale so it can drive a harder bargain when buying drugs and services, not just from pharmaceutical companies, but also the doctors and hospitals that provide patient care.

read full article >

March 5, 2018

BioCentury

De-Risking Risk Reduction

by Erin McCallister

A first-of-its kind value deal between Illumina Inc. and Harvard Pilgrim Health Care Inc. is intended to generate data to support broad reimbursement by multiple payers for non-invasive prenatal tests made by multiple testing companies.

read full article >

January 31, 2018

In Vivo

Biopharma 2018: Is there still a place for pharma in the new health care economy?

by William Looney

Biopharma is not moving as quickly in 2018 as its counterparts in adjacent industry segments, and is confronting a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

read full article >